Bo Ci
Impact in
-
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
-
- Renal cell carcinoma treatment
- Ferroptosis and cancer prognosis
Papers in
-
- Traumatic Brain Injury and Neurovascular Disturbances 2
- Barrier Structure and Function Studies 2
-
- Cancer Genomics and Diagnostics 2
- Co-authors
- Yang Jin Xie (9 shared papers)Guanghua Xiao (5 shared papers)Lin Yang (3 shared papers)David E. Gerber (3 shared papers)Matthew T. MacLean (1 shared paper)Shidan Wang (1 shared paper)Álvaro F. Fernández (1 shared paper)Zhongju Zou (1 shared paper)
- Journals
- Journal of the American Chemical Society (1 paper)European Urology Oncology (1 paper)JCO Clinical Cancer Informatics (1 paper)The Lancet (1 paper)European Journal of Cancer (1 paper)
- Partner nations
- United StatesChinaUnited Kingdom
In The Last Decade
Bo Ci
18 papers receiving 791 citations
Bo Ci's Hit Papers
Peers
Comparison fields: 5 of 86
- Oncology 180
- Pulmonary and Respiratory Medicine 208
- Cancer Research 89
- Epidemiology 165
- Physiology 17
Countries citing papers authored by Bo Ci
This map shows the geographic impact of Bo Ci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo Ci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo Ci more than expected).
Fields of papers citing papers by Bo Ci
This network shows the impact of papers produced by Bo Ci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo Ci. The network helps show where Bo Ci may publish in the future.
Co-authors
The 25 scholars most cited alongside Bo Ci, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2022 | 168 |
| 2 | 2018 | 146 | |
| 3 | 2018 | 115 | |
| 4 | 2018 | 89 | |
| 5 | 2020 | 77 | |
| 6 | 2016 | 51 | |
| 7 | 2019 | 30 | |
| 8 | 2017 | 27 | |
| 9 | 2014 | 26 | |
| 10 | 2018 | 14 | |
| 11 | 2019 | 13 | |
| 12 | 2020 | 8 | |
| 13 | 2022 | 8 | |
| 14 | 2025 | 7 | |
| 15 | 2025 | 7 | |
| 16 | 2020 | 6 | |
| 17 | 2024 | 3 | |
| 18 | 2020 | 2 |
About Bo Ci
Bo Ci is a scholar working on Neurology, Cancer Research, Neurology, Pulmonary and Respiratory Medicine and Pediatrics, Perinatology and Child Health, having authored 18 papers that have together received 797 indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (2 papers), Renal cell carcinoma treatment (2 papers), Neonatal and fetal brain pathology (2 papers), Traumatic Brain Injury and Neurovascular Disturbances (2 papers), Barrier Structure and Function Studies (2 papers), Testicular diseases and treatments (2 papers), Autophagy in Disease and Therapy (2 papers) and Histone Deacetylase Inhibitors Research (1 paper). The work is most often cited by research in Oncology (180 citations), Pulmonary and Respiratory Medicine (208 citations), Cancer Research (89 citations), Epidemiology (165 citations) and Physiology (17 citations). Bo Ci has collaborated with scholars based in United States, China and United Kingdom. Frequent co-authors include Yang Jin Xie, Guanghua Xiao, Lin Yang, David E. Gerber, Matthew T. MacLean, Shidan Wang, Álvaro F. Fernández, Zhongju Zou, Beth Levine and Silvia Vega-Rubín-de-Celis. Their work appears in journals such as Journal of the American Chemical Society, European Urology Oncology, JCO Clinical Cancer Informatics, The Lancet and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.